CorNova
Burlington, Massachusetts, United States
About CorNova
CorNova® is a developer of next-generation endovascular products designed to integrate new technologies into existing products and procedures, resulting in better patient outcomes without added procedure time and patient risk. The FiberHalo™ stent deployment catheter will enable the physician to deploy a stent and measure in-stent lumen area during the procedure. The FiberHalo™ post-dilatation catheter will enable the physician to correct for any under-expansion and also measure post-dilatation results. CorNova is also developing a pre-dilatation version of the FiberHalo™, which will enable the physician to determine likelihood of mechanical failure of stent deployment, allowing for better decision making. CorNova has recently received CE certification on the Valecor Platinum™ stent (a bare metal stent with a pure platinum surface for increased biocompatibility and designed to reduce arterial injury), which has shown superior performance and anti-restenosis properties compared to current bare metal stents.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $10.9M
- Last round: Series Unknown (Jan 2011)
- Website: cornova.com
- Phone: +1 781-270-0055
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cornova-2496961 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.